📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Loading analysis...
MPS Limited Appoints Deepti Singh as Chief People Officer to Drive Global Talent Strategy
MPS Limited has appointed Ms. Deepti Singh as Chief People Officer and Senior Management Personnel, effective March 23, 2026. With over 16 years of experience at high-growth firms like Flipkart and Incedo, her mandate is to align human capital with the company's goal of maintaining industry-leading EBITDA margins. She will specifically focus on integrating recent acquisitions like Unbound Medicine and scaling talent for the healthcare knowledge market. This strategic hire aims to instill a culture of surgical efficiency and high performance across the global organization.
Key Highlights
Ms. Deepti Singh brings over 16 years of global HR leadership experience from companies including Flipkart, Incedo, and Target India.
Mandate includes driving a high-performance culture to support the company's objective of maintaining top-tier EBITDA margins.
Responsible for the people-side integration of recent and future acquisitions, such as Unbound Medicine.
Strategic focus on value engineering in human capital to optimize operational costs and scale the global talent pool.
Appointment is effective from the commencement of business hours on March 23, 2026.
💼 Action for Investors
Investors should view this as a positive step toward institutionalizing operational efficiency and managing the complexities of recent acquisitions. Monitor the company's ability to maintain its high margins as it scales its global workforce under new leadership.
Loading analysis...
MPS Limited Acquires Unbound Medicine to Target $188B Healthcare AI Market
MPS Limited has detailed its acquisition of Unbound Medicine, Inc., a US-based leader in healthcare knowledge management, to pivot toward high-growth AI-driven intelligence. Unbound brings a robust subscription-based model with over 90,000 paid subscribers and 1,000+ healthcare facility clients. The acquisition targets a healthcare AI market projected to reach $188 billion by 2030, with a specific subsector CAGR of 42%. MPS plans to leverage its global infrastructure to expand Unbound's reach beyond North America into Europe and APAC, aiming for significant EBITDA uplift.
Key Highlights
Unbound Medicine serves 1,000+ healthcare facilities and manages 5 million+ clinical lookups annually.
The business model is recurring revenue-based with low concentration risk; the largest customer contributes <$300,000.
Targets the AI-driven knowledge management market, expected to grow from $3 billion to $102 billion by 2034.
Acquisition includes a multidisciplinary team with an average tenure of 12 years and 20+ years of clinical expertise.
Strategic alignment with 'Vision 2027' to transition MPS from a content provider to a global intelligence powerhouse.
💼 Action for Investors
Investors should look favorably on this acquisition as it shifts the company toward high-margin, recurring SaaS revenue in the resilient healthcare sector. Monitor the speed of global rollout and EBITDA margin improvements in subsequent quarters as integration synergies kick in.
Loading analysis...
MPS Limited Schedules Investor Call on Feb 18 for Unbound Medicine, Inc. Acquisition
MPS Limited has announced an update to its conference call scheduled for February 18, 2026, at 7:00 P.M. IST regarding the acquisition of Unbound Medicine, Inc. The company has added a Zoom audio-video participation option to the existing dial-in facilities to facilitate better investor engagement. The acquisition is being conducted through its wholly-owned subsidiary, MPS North America LLC. Chairman and CEO Rahul Arora will lead the call to discuss the strategic implications of this US-based expansion.
Key Highlights
Conference call scheduled for February 18, 2026, at 7:00 P.M. IST.
Discussion focused on the acquisition of Unbound Medicine, Inc., USA.
Deal executed via MPS North America LLC, a 100% wholly-owned subsidiary.
Management to provide details on the strategic rationale and financial impact of the US acquisition.
💼 Action for Investors
Investors should attend the conference call to understand the valuation and synergy benefits of the Unbound Medicine acquisition. Monitor the impact of this acquisition on the company's North American revenue share and overall margins.
Loading analysis...
MPS Limited to Discuss Acquisition of Unbound Medicine Inc. in Upcoming Call
MPS Limited has scheduled a conference call for February 18, 2026, to provide details on the acquisition of Unbound Medicine, Inc., USA. The acquisition is being executed through its wholly-owned subsidiary, MPS North America LLC. Chairman and CEO Rahul Arora will lead the discussion to explain the strategic rationale and expected synergies. This move highlights the company's ongoing focus on inorganic growth and expansion within the North American market.
Key Highlights
Conference call scheduled for Wednesday, February 18, 2026, at 07:00 P.M. IST.
Acquisition of US-based Unbound Medicine, Inc. by wholly-owned subsidiary MPS North America LLC.
Chairman and CEO Rahul Arora and senior management to address institutional investors and analysts.
Universal dial-in numbers for the event are +91 22 6280 1410 and +91 22 7115 8311.
💼 Action for Investors
Investors should monitor the conference call for specific details regarding the acquisition cost, revenue multiples, and how this integration will impact the company's consolidated margins.
Loading analysis...
MPS Limited Completes Acquisition of Unbound Medicine, USA for USD 16.50 Million
MPS Limited, through its US subsidiary MPS North America LLC, has successfully completed the 100% acquisition of Unbound Medicine, Inc., USA. The transaction was finalized for a total consideration of USD 16.50 million following the satisfaction of customary closing conditions. As a result, Unbound Medicine has become a wholly-owned step-down subsidiary of MPS Limited effective February 9, 2026. This acquisition is part of the company's strategy to expand its footprint in the North American market and enhance its digital health and medical education offerings.
Key Highlights
Acquisition of 100% stake in Unbound Medicine, Inc., USA successfully completed
Total transaction value fixed at USD 16.50 million subject to customary adjustments
Unbound Medicine is now a wholly-owned step-down subsidiary of MPS Limited
Completion follows the Stock Purchase Agreement originally signed on January 30, 2026
Funding arrangements for the acquisition were previously disclosed on February 4, 2026
💼 Action for Investors
Investors should view this as a strategic growth move that strengthens MPS's international presence. Monitor upcoming quarterly results to assess the revenue contribution and margin impact of this new subsidiary.
Loading analysis...
MPS Ltd Q3 FY26: 9M Revenue INR 563.2 Cr, Unbound Medicine Acquisition for $16.5M
MPS Limited reported a steady 9M FY26 performance with revenue reaching INR 563.2 crores, despite a slight dip in Q3 revenue to INR 182.5 crores. The Education Solutions segment showed robust growth of 38% in the first nine months, while Research Solutions remained the anchor with 61.1% revenue contribution. A major highlight is the USD 16.5 million acquisition of Unbound Medicine, a high-margin subscription business in the medical and nursing sector. Management remains confident in surpassing an EPS of INR 100 for FY26, supported by aggressive cost optimization and new synergies.
Key Highlights
9M FY26 revenue reached INR 563.2 crores with Education Solutions segment growing over 38%
Q3 FY26 EBITDA margin stood at 31.6%, with the Education segment margins reaching 40.8%
Research Solutions contributed 61.1% of 9M revenue with 16.2% organic growth excluding AJE
Acquired 100% of Unbound Medicine for USD 16.5 million to secure high-margin recurring revenue
Management targets FY26 EPS to exceed INR 100, driven by cost optimization and platform synergies
💼 Action for Investors
Investors should monitor the integration of Unbound Medicine as it shifts the business toward higher-margin recurring revenue. The management's confidence in achieving an EPS of INR 100+ suggests strong underlying profitability despite a transitional third quarter.
Loading analysis...
MPS Ltd Finalizes Funding for $16.5M Acquisition of Unbound Medicine via Debt and Accruals
MPS Limited has outlined a comprehensive funding structure for its USD 16.50 million acquisition of Unbound Medicine, Inc. The acquisition will be financed through a mix of internal accruals, inter-company loans totaling USD 4.94 million, and a new INR 420 million term loan from ICICI Bank. The company is infusing USD 9.81 million as equity into its US subsidiary, MPS North America LLC, to facilitate the transaction. This structured financing ensures the acquisition proceeds without diluting the parent company's 100% stake in its US operations.
Key Highlights
Total acquisition consideration for Unbound Medicine, Inc. is USD 16.50 million.
Secured an INR 420 million term loan from ICICI Bank at a competitive interest rate of 7.85%.
Inter-company loans of USD 3.00 million and USD 1.94 million arranged to optimize group liquidity.
MPS Limited to infuse USD 9.81 million in equity into its wholly-owned subsidiary MPS North America LLC.
Funding involves a balanced mix of internal cash reserves and external borrowings.
💼 Action for Investors
Investors should view this as a positive step toward inorganic growth, with a clear and structured financing plan in place. Monitor the integration of Unbound Medicine and its contribution to the company's consolidated revenue and margins in upcoming quarters.
Loading analysis...
MPS Ltd Q3 PAT at ₹24.7 Cr; 9M Profit Jumps 25.8% YoY; Director Resigns
MPS Limited reported a steady performance for the nine-month period ended December 2025, with standalone net profit rising 25.8% YoY to ₹81.68 crore. However, Q3 FY26 standalone revenue saw a marginal decline to ₹111.20 crore from ₹113.27 crore in the corresponding quarter last year. The company also announced the resignation of Ms. Yamini Tandon, a Non-Executive Director and Chairperson of the Stakeholders’ Relationship Committee, effective February 2, 2026. Additionally, the board approved the grant of 28,906 ESOPs to employees during the quarter.
Key Highlights
Standalone Net Profit for 9M FY26 increased to ₹81.68 crore from ₹64.92 crore in 9M FY25.
Q3 FY26 Revenue from operations stood at ₹111.20 crore, slightly down from ₹113.27 crore YoY.
Basic Earnings Per Share (EPS) for the quarter ended December 31, 2025, was ₹14.44.
Ms. Yamini Tandon resigned from the Board and all committees due to personal reasons.
The company granted 28,906 stock options under the MPS Limited- Employee Stock Options Scheme 2023.
💼 Action for Investors
Investors should look past the marginal Q3 revenue dip and focus on the strong 25.8% growth in nine-month profitability. Monitor the transition in the Stakeholders’ Relationship Committee following the director's resignation.
Loading analysis...
MPS Ltd Q3 FY26 Net Profit Rises 31.5% YoY to ₹28.52 Cr; Revenue Up 28% YoY
MPS Limited reported a strong year-on-year performance for Q3 FY26, with standalone revenue growing 28.2% to ₹111.20 crore compared to ₹86.74 crore in the previous year. Net profit for the quarter stood at ₹28.52 crore, marking a 31.5% increase YoY, despite a marginal 1.8% dip in revenue on a sequential basis. The company also announced the resignation of Non-Executive Director Ms. Yamini Tandon and approved amendments to its Insider Trading Code. Additionally, the board noted the grant of 28,906 ESOPs to eligible employees during the quarter.
Key Highlights
Standalone Revenue from operations grew 28.2% YoY to ₹11,120 lakhs in Q3 FY26.
Net Profit increased by 31.5% YoY to ₹2,852 lakhs from ₹2,168 lakhs in the same quarter last year.
Learning Solutions segment contributed ₹5,157 lakhs to revenue, while Content Solutions added ₹5,076 lakhs.
Basic EPS improved significantly to ₹16.66 from ₹12.67 in the corresponding quarter of the previous year.
Ms. Yamini Tandon resigned as Non-Executive Director effective February 2, 2026, due to personal reasons.
💼 Action for Investors
Investors should take note of the robust year-on-year growth and healthy margins, which indicate strong operational execution. While the slight sequential revenue dip should be monitored, the overall financial trajectory remains positive for long-term holders.
Loading analysis...
MPS Limited Q3 FY26: PAT at ₹35.5 Cr; On Track for Record ₹100+ EPS in FY26
MPS Limited reported a resilient performance for Q3 FY26 with revenues of ₹182.5 crore, despite a marginal 2.1% YoY decline. The core Research Solutions segment (excluding AJE) showed strong growth of 16.2% YoY, while Education Solutions grew by 11.3%. The company remains debt-free with a strong cash position of ₹143 crore and is confident of achieving its first-ever annual EPS of ₹100+ for FY26. Profitability in Q3 was impacted by a ₹7.02 crore exceptional provision related to the New Labour Code.
Key Highlights
9M FY26 PAT grew by 23.9% YoY to ₹126.2 crore, with EBITDA margins improving to 29.9%.
Research Solutions (excl. AJE) revenue grew 16.2% YoY, maintaining a high EBITDA margin of 39.1%.
Education Solutions segment revenue increased 11.3% YoY to ₹44.3 crore with 40.8% EBITDA margins.
Company maintains a debt-free balance sheet with cash and equivalents of ₹143 crore as of Dec 2025.
Management expects to surpass ₹100 EPS for the first time in the company's history in FY26.
💼 Action for Investors
Investors should focus on the strong 9M growth trajectory and the management's confidence in achieving record EPS. The core strength in Research and Education segments makes this a solid long-term play despite the temporary reset in Corporate Learning.
Loading analysis...
MPS Ltd Q3 FY26 Results: Net Profit Rises 15.5% YoY to ₹28.52 Cr; Revenue Up 23.6%
MPS Limited reported a strong performance for Q3 FY26, with revenue from operations growing 23.6% YoY to ₹111.20 crore. Net profit for the quarter increased by 15.5% YoY to ₹28.52 crore, supported by growth across its Content and Learning solutions segments. The company's EPS improved to ₹16.71 from ₹14.47 in the same quarter last year. Additionally, the board noted the resignation of Non-Executive Director Ms. Yamini Tandon and approved amendments to the insider trading code.
Key Highlights
Revenue from operations grew 23.6% YoY to ₹11,120 lakhs in Q3 FY26.
Net profit increased 15.5% YoY to ₹2,852 lakhs, compared to ₹2,470 lakhs in Q3 FY25.
Content Solutions remains the largest segment, contributing ₹5,688 lakhs to quarterly revenue.
Basic EPS for the quarter rose to ₹16.71 from ₹14.47 in the previous year's corresponding quarter.
Nine-month (9M FY26) total income reached ₹32,880 lakhs with a net profit of ₹8,492 lakhs.
💼 Action for Investors
Investors should view the consistent double-digit growth in revenue and profit as a sign of operational strength. The stock remains a positive hold given the steady margin profile and segment diversification.
Loading analysis...
MPS Limited Acquires 100% Stake in US-Based Healthcare Tech Firm Unbound Medicine
MPS Limited, through its US subsidiary, has entered into an agreement to acquire a 100% stake in Unbound Medicine, Inc., a Delaware-based healthcare technology company. Founded in 1999, Unbound Medicine provides digital medical reference and clinical decision-support solutions via a subscription-led institutional model. This acquisition marks MPS's strategic entry into the high-growth healthcare and medical information technology segment. The move aligns with the company's 'Vision 2027' strategy to focus on high-quality, recurring-revenue businesses with strong customer stickiness in the North American market.
Key Highlights
Acquisition of 100% stake in Unbound Medicine, Inc. by wholly-owned subsidiary MPS North America LLC.
Unbound Medicine has a 26-year operational history serving leading medical schools and hospital systems in the US and Canada.
The target company operates a subscription-led business model, ensuring resilient and recurring revenue streams.
Strategic expansion into the healthcare vertical, diversifying MPS's portfolio beyond core digital publishing.
Integration with MPS Labs intended to accelerate AI-driven innovation in clinical tools and medical platforms.
💼 Action for Investors
This acquisition is a significant positive as it adds a high-margin, recurring revenue stream in a specialized vertical. Investors should monitor upcoming financial disclosures for the deal valuation and the impact on consolidated EBITDA margins.
Loading analysis...
MPS Ltd to Acquire US-based Unbound Medicine for USD 16.5 Million
MPS Limited, through its US subsidiary, has entered into an agreement to acquire a 100% stake in Unbound Medicine, Inc. for USD 16.50 million in cash. Unbound Medicine is a healthcare learning technology company that reported USD 8.88 million in revenue for CY2024. The acquisition provides MPS entry into the high-growth medical information technology segment and adds over 480 institutional clients to its portfolio. This move is part of MPS's strategic vision to reach INR 1,500 crore in revenue by FY28.
Key Highlights
Acquisition of 100% stake for a total cash consideration of USD 16.50 million
Target entity reported CY2024 revenue of USD 8.88 million with a high gross retention rate of ~97%
Adds 480+ institutional customers including medical schools and hospital systems across the US and Canada
Strategic entry into AI-enabled clinical decision support and healthcare learning platforms
Transaction expected to be completed on or before 10 February 2026
💼 Action for Investors
Investors should view this as a positive strategic expansion into a high-margin, recurring revenue vertical that complements MPS's existing digital publishing business. Monitor the integration progress and the impact on consolidated margins in upcoming quarters.